Squamous Cell Carcinoma of Head and NeckPhase 2NCT00371566
A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck Cancer
A Phase 2 study testing Lapatinib oral tablets in people with Squamous Cell Carcinoma of Head and Neck, run by GlaxoSmithKline at 9 sites in 5 countries.
Trial summary
This is a study comparing the activity of lapatinib versus placebo followed by chemoradiation. This study is designed to explore the effects of lapatinib monotherapy on apoptosis/necrosis, in pre-treatment and post-treatment tumour tissue samples in subjects with locally advanced squamous cell carcinoma of head and… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Squamous Cell Carcinoma of Head and Neck
- What is being tested?
- Lapatinib oral tablets
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 107 participants
- Where
- 9 sitesin 5 countries
- Study dates
- Mar 2006to Dec 2007
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Willing and able to sign a written informed consent.
- Histologically or cytologically confirmed diagnosis of SCCHN.
- Stage III, IVA and IVB disease will be eligible, who are to receive chemoradiation therapy as primary treatment (total dose ≥ 65 Gy). Subjects with distant metastases (stage IVC) will be excluded.
- Willing and able to have a tumour biopsy taken at screening and a second tumour biopsy taken during lapatinib/placebo administration.
- Male or female ≥18 years of age.
- Criteria for female subjects or female partners of male subjects: Non-child-bearing potential (i.e., women with functioning ovaries who have a current documented tubal ligation or hysterectomy, or women who are postmenopausal); Child-bearing potential (i.e., women with functioning ovaries and no documented impairment of oviductal or uterine function that would cause sterility.) This category includes women with oligomenorrhoea (severe), women who are perimenopausal, and young women who have begun to menstruate. These subjects must have a negative serum pregnancy test at screening and agree to one of the following:
Show all 16Show fewer
- Complete abstinence from intercourse from 2 weeks prior to administration of the first dose of study medication until 28 days after the final dose of study medication; or
- Consistent and correct use of one of the following acceptable methods of birth control:
- male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female subject; implants of levonorgestrel; injectable progestogen; any intrauterine device (IUD) with a documented failure rate of less than 1% per year; oral contraceptives (either combined or progestogen only); or barrier methods, including diaphragm or condom with a spermicide.
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.
- Subjects must have adequate haematological, renal and hepatic function. Calculated creatinine clearance ≥50 ml/min as determined by the method of Cockcroft and Gault [Cockcroft, 1976] or by the EDTA method.
- Absolute neutrophil count ≥1,500/μl, platelets ≥100,000/μl. Haemoglobin ≥9gm/dL (5mmol/L). Aspartate (AST) and alanine transaminase (ALT) less than three times the upper limit of the normal range (ULN).
- Total bilirubin ≤2.0 mg/dL.
- Left ventricular ejection fraction (LVEF) within the institutional normal ranges as measured by echocardiogram (ECHO) or Multigated Acquisition (MUGA) scans.
- Able to swallow tablet whole or swallow a suspension of the tablet dissolved in water at study inclusion. If necessary, the suspension may be administered via percutaneous endoscopic gastrostomy (PEG), percutaneous jejunostomy tube (JTube), or a nasogastric tube (NG or Dobhoff type tube).
- Life expectancy of at least 6 months as judged by the investigator.
Who cannot join
- Subjects with paranasal sinuses, nasopharyngeal and nasal cavity tumours;
- Subjects who have received prior systemic chemotherapy given with curative intent;
- Subjects who received prior radiotherapy;
- Prior or concurrent treatment with tyrosine kinase inhibitors;
- Use of any investigational agent within 30 days or 5 half-lives, whichever is longer, preceding the first dose of lapatinib;
- Concurrent use of CYP3A4 inducers or inhibitors;
Show all 17Show fewer
- Subjects with known history of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure;
- History of another malignancy within the last 5 years, with the exception of completely resected basal or squamous cell skin cancer, or successfully treated in situ carcinoma. History of non-invasive lesion or in-situ carcinoma of head and neck that was successfully treated with surgery, photodynamics or laser, will be permitted;
- Distant metastases, ie Stage IVC;
- Females or males of child-bearing potential who are sexually active, if they do not agree to practice an effective method of contraception. (For example oral contraceptives, IUD or diaphragm plus spermicide);
- Pregnant or lactating females (female patients of childbearing potential will undertake pregnancy testing at screening and during study completion/withdrawal visits);
- Malabsorption syndrome, disease significantly affecting GI function, that could affect absorption of lapatinib;
- History of allergic reactions to appropriate diuretics or antiemetics (e.g. 5-HT3 antagonists) to be administered with platinum-based chemotherapy;
- The investigator considers the patient unfit for the study as a result of the medical interview, physical examinations, or screening investigations;
- Subjects taking any prohibited medication (See Section 8.2)
- Other Eligibility Criteria Considerations:
- To assess any potential impact on subject eligibility with regard to safety, the investigator must refer to the following document(s) for detailed information regarding warnings,precautions, contraindications, adverse events, and other significant data pertaining to the investigational product(s) being used in this study: investigator's brochure IB and any IB supplements, and expedited investigator safety reports
Trial locations and contacts
9 sites in 5 countries.
9 sites in 5 countries
France3 sites
GSK Investigational Site
Caen, 14076
GSK Investigational Site
Montpellier, 34298
GSK Investigational Site
Villejuif, 94805
India2 sites
GSK Investigational Site
Bangalore, 560029
GSK Investigational Site
Thiruvananthapuram, 695 011
Spain2 sites
GSK Investigational Site
Barcelona, 08035
GSK Investigational Site
Madrid, 28041
About this study
Official title: A Randomized, Single Blinded, Placebo-controlled, Multi-centre, Phase II Study of Lapatinib in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
This is a study comparing the activity of lapatinib versus placebo followed by chemoradiation. This study is designed to explore the effects of lapatinib monotherapy on apoptosis/necrosis, in pre-treatment and post-treatment tumour tissue samples in subjects with locally advanced squamous cell carcinoma of head and neck.
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Being tested
- Lapatinib oral tablets, Placebo
- Keywords
- squamous cell carcinoma of head and neck, lapatinib, ErbB1/ErbB2 inhibitor, apoptosis
- Medical subject headings
- Squamous Cell Carcinoma of Head and Neck
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lapatinib oral tabletsDrug
Also called platinum - based chemotherapy, radiotherapy
PlaceboDrug
| Study group | Role | What they receive |
|---|---|---|
| Lapatinib | Experimental | Not described Receives: Drug: Lapatinib oral tablets |
| Placebo | Placebo comparator | Not described Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline of the Apoptotic Index During Treatment Phase
Apoptotic Index-TUNEL Assay is a method which counts a total of at least 1000 neoplastic nuclei(Cells with morphological changes defining cell death) subdivided in 10 fields chosen randomly at 400x magnification. A 'responder' was defined as having 20% cell death.
Measured: Baseline and Week 2
Secondary outcomes (32)
Change From Baseline of Cell Proliferation Rate of the Ki-67 Proliferative Index in Tumour Biopsy Samples During Treatment Phase
The Ki-67 protein is expressed in all phases of the cell cycle except G0 (low level phase) and serves as a good marker for cell proliferation. Scoring is assessed by point counting 500 to 1000 cells, and is reported as percent positive cells. 20% positive cells to define "positive" (i.e. high risk)
Measured: Baseline and Week 2
Overall Radiological Response After Treatment Phase in mITT Population
Over all: Complete Response (CR)- absence of lesions. Partial Response (PR)- CR or PR of target lesions and incomplete response (IC) or stable disease (SD) in other lesions with no new lesions or progressive disease (PD). Stable Disease (SD)-no PD or Response. Progressive Disease (PD)-PD or new lesions. Not Evaluable(NE)- no other definitions. Number of subjects included those who had a scan immediately post lapatanib/placebo monotherapy.
Measured: Baseline and End of Treatment (Week 2 - 6)
Overall Radiological Response After Follow-up Phase in mITT Population
Over all: Complete Response(CR)-absence of lesions. Partial Response(PR)- CR or PR of target lesions and incomplete response (IC) or stable disease (SD)in other lesions with no new lesions or progressive disease (PD). Stable Disease(SD)-no PD or Response. Progressive Disease(PD)-PD or new lesions. Not Evaluable(NE)- no other definitions. Number of subjects included those who were considered evaluable if they completed a full course of chemoradiotherapy and were able to provide a baseline and follow-up scan following the completion of chemoradiation.
Measured: Baseline and End of Follow-up (Week 19 - 25)
Overall Radiological Response After Treatment Phase in ITT Population
Over all: Complete Response (CR)-absence of lesions. Partial Response (PR)- CR or PR of target lesions and incomplete response (IC) or stable disease (SD) in other lesions with no new lesions or progressive disease (PD). Stable Disease (SD)-no PD or Response. Progressive Disease (PD)-PD or new lesions. Not Evaluable(NE)- no other definitions.
Measured: Baseline and End of Treatment (Week 2 - 6)
Overall Radiological Response After Follow-up Phase in ITT Population
Over all: Complete Response (CR) - absence of lesions. Partial Response (PR) - CR or PR of target lesions and incomplete response (IC) or stable disease (SD) in other lesions with no new lesions or progressive disease (PD). Stable Disease (SD)- no PD or Response. Progressive Disease (PD)- PD or new lesions. Not Evaluable(NE)- no other definitions.
Measured: Baseline and End of Follow-up (week 19 - 25)
Number of Circulating Tumor Cells at Baseline in mITT Population
This measures the participants with Circulating Tumor Cells (CTC's)Pre-Treatment numbers of 0 to >= 4. CTC's are tumor cells that escape from the primary tumor into the bloodstream and travel through the circulation to distant sites where they develop into secondary tumors.
Measured: Baseline
Number of Participants With Circulating Tumor Cells After Treatment Phase in mITT Population
This measures the participants with Circulating Tumor Cells (CTC's) after treatment numbers of 0 to >= 4. CTC's are tumor cells that escape from the primary tumor into the bloodstream and travel through the circulation to distant sites where they develop into secondary tumors.
Measured: End of Treatment (week 2 - 6)
Number of Participants With Circulating Tumor Cells After Chemoradiotherapy Phase in mITT Population
This measures the participants with Circulating Tumor Cells (CTC's) after chemoradiotherapy numbers of 0 to >= 4. CTC's are tumor cells that escape from the primary tumor into the bloodstream and travel through the circulation to distant sites where they develop into secondary tumors.
Measured: End of Chemoradiotherapy (week 10 - 13)
Number of Biomarkers Including ErbB1, ErbB2, pErbB1, and pErb2 at Baseline and During Treatment Phase
Estrogen Receptor (ER) variants, ERB-B2 and ERB B-5 consist of the major proportion of ER expression both in normal and cancer tissues. The exact role of these markers are unknown. Acronyms defined: ICH (immunohistochemical) and FISH (fluorescence in situ hybridization).
Measured: Baseline and Week 2
Number of Biomarkers Including Tumor Protein 53 and HPV During Treatment Phase
Tumor Suppressor p53 is welcomed and described as "the guardian angel gene," it conserves stability by preventing genome mutation. Human Papillomavirus (HPV) biomarker is un-welcomed and is found to be an important precursor cancers of the head and neck. HPV biomarkers have the ability to bind to and inactivate the Tumor Suppressor p53 biomarker.
Measured: Week 2
Summary of Adverse Events by Maximum Toxicity Grade Started During Treatment Phase
Toxicity Grading scale 0=none, 1=transient symptom, 2=mild symptom that does not interfere with activities of daily living (ADL's) 3=mild but interfers with ADL's w/o hospitalization. 4=requires hopitalization 5=Death.
Measured: Week 1 through Week 6
Summary of Adverse Events by Maximum Toxicity Grade (Grade 3 or Higher) Started During or After the Chemoradiotherapy Phase
Toxicity Grading scale 0=none, 1= transient symptom, 2=mild symptom that does not interfere with activities of daily living (ADL's) 3=mild but interfers with ADL's w/o hospitalization. 4=requires hopitalization 5=Death.
Measured: Week 10 through 25
Comparison of Overall Response During Treatment Phase Using CT/MRI and PET Information
Position Emission Tomography (PET) scans 3-D images are read alongside CT or magnetic resonance imaging (MRI) scans, the combination gives both anatomic and metabolic information. CT = Computerized axial tomography; a type of x-ray for dense areas of the body. MRI = Magnetic Resonance Imaging which captures a picture using Magnets. Better = improvement in response, Worse = response was downgraded.
Measured: Week 2 - 4
Comparison of Overall Response During Follow up Phase Using CT/MRI and PET Information
Position Emission Tomography (PET) scans 3-D images are read alongside CT or magnetic resonance imaging (MRI) scans, the combination gives both anatomic and metabolic information. CT = Computerized axial tomography; a type of x-ray for dense areas of the body. MRI = Magnetic Resonance Imaging which captures a picture using Magnets. Better = improvement in response, Worse = response was downgraded.
Measured: weeks 19 - 25
Summary of Adverse Events Experienced by 15% or More Subjects in Either Treatment Group
Definition of an adverse event is any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Measured: Week 1 through 25
Summary of Fatal/Serious Adverse Events During or After Chemoradiotherapy Phase
Events which started during or After the Chemoradiotherapy Phase. Definition of a serious adverse event is any untoward medicinal occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other.
Measured: Week 10 through 25
Summary of Serious Adverse Events During or After Chemoradiotherapy Phase
Events which started during or After Chemoradiotherapy Phase. Definition of a serious adverse event is any untoward medicinal occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other.
Measured: Week 10 through 25
Adverse Events by Maximum Toxicity Grade 3 During or After Chemoradiotherapy Phase
Events which started during or after Chemoradiotherapy Phase. "Grade 3" are severe and undesirable Adverse Event (significant symptoms requiring hospitalization or invasive intervention; transfusion; elective interventional radiological procedure; therapeutic endoscopy or operation).
Measured: Week 10 through 25
Adverse Events (AEs) by Maximum Toxicity Grade 4 During or After Chemoradiotherapy Phase
Events which started during or after Chemoradiotherapy Phase. "Grade 4" are life-threatening or disabling Adverse Event (complicated by acute, life-threatening metabolic or cardiovascular complications such as circulatory failure, hemorrhage, sepsis. Life-threatening physiologic consequences; need for intensive care or emergent invasive procedure; emergent interventional radiological procedure, therapeutic endoscopy or operation).
Measured: Week 10 through 25
Adverse Events by Maximum Toxicity Grade 5 During or After Chemoradiotherapy Phase
Events which started during or after Chemoradiotherapy Phase. "Grade 5" are death related to Adverse Event.
Measured: Week 10 through 25
Relative Change From Baseline of Ktrans Median (1/Min) After 2 - 4 Weeks of Treatment
Dynamic Contrast enhanced Magnetic Resonance Imaging (DCE-MRI) tracks the diffusion of an administered contrast agent from -intra into the extravascular tissue over time. Ktrans estimates blood flow and relates to the ease of exchange into extravascular spaces. A volume transfer (i.e, 1/min) constant of contrast agent is used to determine vascular permeability. By plugging DCE-MRI results into an appropriate pharmacokinetic model, physiological parameters of the tumor (e.g.,tissue perfusion, vessel permeability, vascular surface area, and extracellular/vascular volume fraction) are determined.
Measured: Baseline, and Week 2 - 4
Relative Change From Baseline of Kep Mean (1/Min) After 2 - 4 Weeks of Treatment
DCE-MRI tracks the diffusion of an intravascularly administered contrast agent into the extravascular tissue over time. Over a period of time, the contrast agent diffuses back into the vasculature (described by the rate constant or Kep). The lower the Kep, the longer the contrast remains in the extravascular space and is more prolonged. A volume transfer (i.e, 1/min) constant of contrast agent is used to determine vascular permeability. By plugging DCE-MRI results into an appropriate pharmacokinetic model, physiological parameters of the tumor (e.g., vessel permeability, etc.) are determined.
Measured: Baseline, and Week 2 - 4
Relative Change From Baseline of Kep Perfused (1/Min) After 2 - 4 Weeks of Treatment
DCE-MRI tracks the diffusion of an intravascularly administered contrast agent into the extravascular tissue over time. Over a period of time, the contrast agent diffuses back into the vasculature (described by the rate constant or Kep). The lower the Kep, the longer the contrast remains in the extravascular space and is more prolonged. A volume transfer (i.e, 1/min) constant of contrast agent is used to determine vascular permeability. By plugging DCE-MRI results into an appropriate pharmacokinetic model, physiological parameters of the tumor (e.g., vessel permeability, etc.) are determined.
Measured: Baseline, and Week 2 - 4
Relative Change From Baseline of Kep Whole (1/Min) After 2 - 4 Weeks of Treatment
DCE-MRI tracks the diffusion of an intravascularly administered contrast agent into the extravascular tissue over time. Over a period of time, the contrast agent diffuses back into the vasculature (described by the rate constant or Kep). The lower the Kep, the longer the contrast remains in the extravascular space and is more prolonged. A volume transfer (i.e, 1/min) constant of contrast agent is used to determine vascular permeability. By plugging DCE-MRI results into an appropriate pharmacokinetic model, physiological parameters of the tumor (e.g., vessel permeability, etc.) are determined.
Measured: Baseline, and Week 2 - 4
Relative Change From Baseline of Ktrans Mean (1/Min) After 2 - 4 Weeks of Treatment
Dynamic Contrast enhanced Magnetic Resonance Imaging (DCE-MRI) tracks the diffusion of an administered contrast agent from -intra into the extravascular tissue over time. Ktrans estimates blood flow and relates to the ease of exchange into extravascular spaces. A volume transfer (i.e, 1/min) constant of contrast agent is used to determine vascular permeability. By plugging DCE-MRI results into an appropriate pharmacokinetic model, physiological parameters of the tumor (e.g.,tissue perfusion, vessel permeability, vascular surface area, and extracellular/vascular volume fraction) are determined.
Measured: Baseline, and Week 2 - 4
Relative Change From Baseline of Ktrans Perfused (1/Min) After 2 - 4 Weeks of Treatment
Dynamic Contrast enhanced Magnetic Resonance Imaging (DCE-MRI) tracks the diffusion of an administered contrast agent from -intra into the extravascular tissue over time. Ktrans estimates blood flow and relates to the ease of exchange into extravascular spaces. A volume transfer (i.e, 1/min) constant of contrast agent is used to determine vascular permeability. By plugging DCE-MRI results into an appropriate pharmacokinetic model, physiological parameters of the tumor (e.g.,tissue perfusion, vessel permeability, vascular surface area, and extracellular/vascular volume fraction) are determined.
Measured: Baseline, and Week 2 - 4
Relative Change From Baseline of Ktrans Whole (1/Min) After 2 - 4 Weeks of Treatment
Dynamic Contrast enhanced Magnetic Resonance Imaging (DCE-MRI) tracks the diffusion of an administered contrast agent from -intra into the extravascular tissue over time. Ktrans estimates blood flow and relates to the ease of exchange into extravascular spaces. A volume transfer (i.e, 1/min) constant of contrast agent is used to determine vascular permeability. By plugging DCE-MRI results into an appropriate pharmacokinetic model, physiological parameters of the tumor (e.g.,tissue perfusion, vessel permeability, vascular surface area, and extracellular/vascular volume fraction) are determined.
Measured: Baseline, and Week 2 - 4
Relative Change From Baseline of IAUC Median (90) After 2 - 4 Weeks of Treatment
Dynamic Contrast - enhanced Magnetic Resonance Imaging (DCE-MRI) tracks the diffusion of an intravascularly administered contrast agent from intravascular into the extravascular tissue over time. Initial area under the contrast (IAUC), tracks the concentration versus time curve 90 seconds after contrast injection (IAUC90). By plugging DCE-MRI results into an appropriate pharmacokinetic model, physiological parameters of the tumor microenvironment (e.g., tissue perfusion, vessel permeability, vascular surface area, and extracellular-extra vascular volume fraction) are determined.
Measured: Baseline, and Week 2 - 4
Relative Change From Baseline of IAUC Mean (90) After 2 - 4 Weeks of Treatment
Dynamic Contrast - enhanced Magnetic Resonance Imaging (DCE-MRI) tracks the diffusion of an intravascularly administered contrast agent from intravascular into the extravascular tissue over time. Initial area under the contrast (IAUC), tracks the concentration versus time curve 90 seconds after contrast injection (IAUC90). By plugging DCE-MRI results into an appropriate pharmacokinetic model, physiological parameters of the tumor microenvironment (e.g., tissue perfusion, vessel permeability, vascular surface area, and extracellular-extra vascular volume fraction) are determined.
Measured: Baseline, and Week 2 - 4
Relative Change From Baseline of Perfused IAUC (90) After 2 - 4 Weeks of Treatment
Dynamic Contrast - enhanced Magnetic Resonance Imaging (DCE-MRI) tracks the diffusion of an intravascularly administered contrast agent from intravascular into the extravascular tissue over time. Initial area under the contrast (IAUC), tracks the concentration versus time curve 90 seconds after contrast injection (IAUC90). By plugging DCE-MRI results into an appropriate pharmacokinetic model, physiological parameters of the tumor microenvironment (e.g., tissue perfusion, vessel permeability, vascular surface area, and extracellular-extra vascular volume fraction) are determined.
Measured: Baseline, and Week 2 - 4
Relative Change From Baseline of Whole IAUC(90) After 2 - 4 Weeks of Treatment
Dynamic Contrast - enhanced Magnetic Resonance Imaging (DCE-MRI) tracks the diffusion of an intravascularly administered contrast agent from intravascular into the extravascular tissue over time. Initial area under the contrast (IAUC), tracks the concentration versus time curve 90 seconds after contrast injection (IAUC90). By plugging DCE-MRI results into an appropriate pharmacokinetic model, physiological parameters of the tumor microenvironment (e.g., tissue perfusion, vessel permeability, vascular surface area, and extracellular-extra vascular volume fraction) are determined.
Measured: Baseline, and Week 2 - 4
Relative Change From Baseline of Kep Median (1/Min) After 2 - 4 Weeks of Treatment
DCE-MRI tracks the diffusion of an intravascularly administered contrast agent into the extravascular tissue over time. Over a period of time, the contrast agent diffuses back into the vasculature (described by the rate constant or Kep). The lower the Kep, the longer the contrast remains in the extravascular space and is more prolonged. A volume transfer (i.e, 1/min) constant of contrast agent is used to determine vascular permeability. By plugging DCE-MRI results into an appropriate pharmacokinetic model, physiological parameters of the tumor (e.g., vessel permeability, etc.) are determined.
Measured: Baseline, and Week 2 - 4
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Sep 2006 (estimated)
- Study startMar 2006
- Primary completionDec 2007
- Study completionDec 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Squamous Cell Carcinoma of Head and NeckStudies of the same condition, open and under way.
- More trials run by GlaxoSmithKlineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Enrolment
- 107 participants (actual)
Sponsor and investigators
- Lead sponsor
- GlaxoSmithKline
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- GSK Clinical Trials, MD, PhD, Study director, GlaxoSmithKline
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00371566
- Sponsor's protocol ID
- EGF104334
- Status last verified
- Apr 2010
- First submitted
- 31 Aug 2006
- Last updated
- 6 Apr 2010
- Results posted
- Yes, on ClinicalTrials.gov
Study at a glance
From the registry record, last updated by the sponsor on 6 Apr 2010. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Single Blinded, Placebo-controlled, Multi-centre, Phase II Study of Lapatinib in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- ClinicalTrials.gov ID
- NCT00371566
- Acronym / sponsor ID
- EGF104334
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Keywords
- squamous cell carcinoma of head and neck, lapatinib, ErbB1/ErbB2 inhibitor, apoptosis
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 107 participants (actual)
- Lead sponsor
- GlaxoSmithKlineIndustry (pharma, biotech, devices)
- Study start
- Mar 2006
- Primary completion
- Dec 2007 (actual)
- Study completion
- Dec 2007 (actual)
- First posted
- 4 Sep 2006 (estimated)
- Results
- Posted 29 Jan 2010
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a study comparing the activity of lapatinib versus placebo followed by chemoradiation. This study is designed to explore the effects of lapatinib monotherapy on apoptosis/necrosis, in pre-treatment and post-treatment tumour tissue samples in subjects with locally advanced squamous cell carcinoma of head and neck.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Lapatinib | Experimental | Drug: Lapatinib oral tablets |
| Placebo | Placebo comparator | Drug: Placebo |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (16 listed)
- Willing and able to sign a written informed consent.
- Histologically or cytologically confirmed diagnosis of SCCHN.
- Stage III, IVA and IVB disease will be eligible, who are to receive chemoradiation therapy as primary treatment (total dose ≥ 65 Gy). Subjects with distant metastases (stage IVC) will be excluded.
- Willing and able to have a tumour biopsy taken at screening and a second tumour biopsy taken during lapatinib/placebo administration.
- Male or female ≥18 years of age.
Key exclusion criteria (17 listed)
- Subjects with paranasal sinuses, nasopharyngeal and nasal cavity tumours;
- Subjects who have received prior systemic chemotherapy given with curative intent;
- Subjects who received prior radiotherapy;
- Prior or concurrent treatment with tyrosine kinase inhibitors;
- Use of any investigational agent within 30 days or 5 half-lives, whichever is longer, preceding the first dose of lapatinib;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lapatinib oral tabletsAlso: platinum - based chemotherapy, radiotherapy | Drug | Lapatinib |
| Placebo | Drug | Placebo |
Primary outcome
Change From Baseline of the Apoptotic Index During Treatment Phase
Time frame: Baseline and Week 2
Apoptotic Index-TUNEL Assay is a method which counts a total of at least 1000 neoplastic nuclei(Cells with morphological changes defining cell death) subdivided in 10 fields chosen randomly at 400x magnification. A 'responder' was defined as having 20% cell death.
32 secondary outcomes
Change From Baseline of Cell Proliferation Rate of the Ki-67 Proliferative Index in Tumour Biopsy Samples During Treatment Phase
Time frame: Baseline and Week 2
Overall Radiological Response After Treatment Phase in mITT Population
Time frame: Baseline and End of Treatment (Week 2 - 6)
Overall Radiological Response After Follow-up Phase in mITT Population
Time frame: Baseline and End of Follow-up (Week 19 - 25)
Overall Radiological Response After Treatment Phase in ITT Population
Time frame: Baseline and End of Treatment (Week 2 - 6)
Overall Radiological Response After Follow-up Phase in ITT Population
Time frame: Baseline and End of Follow-up (week 19 - 25)
Number of Circulating Tumor Cells at Baseline in mITT Population
Time frame: Baseline
Number of Participants With Circulating Tumor Cells After Treatment Phase in mITT Population
Time frame: End of Treatment (week 2 - 6)
Number of Participants With Circulating Tumor Cells After Chemoradiotherapy Phase in mITT Population
Time frame: End of Chemoradiotherapy (week 10 - 13)
Number of Biomarkers Including ErbB1, ErbB2, pErbB1, and pErb2 at Baseline and During Treatment Phase
Time frame: Baseline and Week 2
Number of Biomarkers Including Tumor Protein 53 and HPV During Treatment Phase
Time frame: Week 2
Summary of Adverse Events by Maximum Toxicity Grade Started During Treatment Phase
Time frame: Week 1 through Week 6
Summary of Adverse Events by Maximum Toxicity Grade (Grade 3 or Higher) Started During or After the Chemoradiotherapy Phase
Time frame: Week 10 through 25
Comparison of Overall Response During Treatment Phase Using CT/MRI and PET Information
Time frame: Week 2 - 4
Comparison of Overall Response During Follow up Phase Using CT/MRI and PET Information
Time frame: weeks 19 - 25
Summary of Adverse Events Experienced by 15% or More Subjects in Either Treatment Group
Time frame: Week 1 through 25
Summary of Fatal/Serious Adverse Events During or After Chemoradiotherapy Phase
Time frame: Week 10 through 25
Summary of Serious Adverse Events During or After Chemoradiotherapy Phase
Time frame: Week 10 through 25
Adverse Events by Maximum Toxicity Grade 3 During or After Chemoradiotherapy Phase
Time frame: Week 10 through 25
Adverse Events (AEs) by Maximum Toxicity Grade 4 During or After Chemoradiotherapy Phase
Time frame: Week 10 through 25
Adverse Events by Maximum Toxicity Grade 5 During or After Chemoradiotherapy Phase
Time frame: Week 10 through 25
Relative Change From Baseline of Ktrans Median (1/Min) After 2 - 4 Weeks of Treatment
Time frame: Baseline, and Week 2 - 4
Relative Change From Baseline of Kep Mean (1/Min) After 2 - 4 Weeks of Treatment
Time frame: Baseline, and Week 2 - 4
Relative Change From Baseline of Kep Perfused (1/Min) After 2 - 4 Weeks of Treatment
Time frame: Baseline, and Week 2 - 4
Relative Change From Baseline of Kep Whole (1/Min) After 2 - 4 Weeks of Treatment
Time frame: Baseline, and Week 2 - 4
Relative Change From Baseline of Ktrans Mean (1/Min) After 2 - 4 Weeks of Treatment
Time frame: Baseline, and Week 2 - 4
Relative Change From Baseline of Ktrans Perfused (1/Min) After 2 - 4 Weeks of Treatment
Time frame: Baseline, and Week 2 - 4
Relative Change From Baseline of Ktrans Whole (1/Min) After 2 - 4 Weeks of Treatment
Time frame: Baseline, and Week 2 - 4
Relative Change From Baseline of IAUC Median (90) After 2 - 4 Weeks of Treatment
Time frame: Baseline, and Week 2 - 4
Relative Change From Baseline of IAUC Mean (90) After 2 - 4 Weeks of Treatment
Time frame: Baseline, and Week 2 - 4
Relative Change From Baseline of Perfused IAUC (90) After 2 - 4 Weeks of Treatment
Time frame: Baseline, and Week 2 - 4
Relative Change From Baseline of Whole IAUC(90) After 2 - 4 Weeks of Treatment
Time frame: Baseline, and Week 2 - 4
Relative Change From Baseline of Kep Median (1/Min) After 2 - 4 Weeks of Treatment
Time frame: Baseline, and Week 2 - 4
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Apr 2010.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Squamous Cell Carcinoma of Head and Neck
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 2
Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial
Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma
RecruitingObservational study
Multicenter Prospective Cohort on Esophageal Endoscopic Submucosal Dissection
Superficial Esophageal Cancer, Oesophageal Adenocarcinoma
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Not yet recruiting
Tumoral Versus Luminal Microbiome in Head and Neck Squamous Cell Carcinoma
Squamous Cell Cancer of Head and Neck (SCCHN)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
GSK Clinical Trials, MD, PhD study director
GlaxoSmithKline
9 sites in 5 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Lapatinib oral tablets in people with Squamous Cell Carcinoma of Head and Neck, run by GlaxoSmithKline at 9 sites in 5 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 16 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Apr 2010. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 9 sites in France, India, Spain, Greece, Peru. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 29 Jan 2010). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline of the Apoptotic Index During Treatment Phase (time frame: Baseline and Week 2). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Apr 2010.